• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- NEWS BRIEFS March 28, 2023

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/news-briefs

Lucira announces US launch of combo COVID-flu home test


News brief

8 minutes ago.
Lisa Schnirring
Topics

Influenza, General

COVID-19

Lucira today announced the US launch of its at-home combination COVID-19 and flu test, the first of its kind, following the February emergency use authorization (EUA) from the Food and Drug Administration (FDA).

The biotechnology company, based in Emeryville, Calif., also announced that the test is now cleared for use as a point-of-care test in Australia.

In earlier clinical trials, the molecular test has performed similarly for both COVID and flu when assessed against polymerase chain reaction (PCR) tests. Lucira's combo test also marks the availability of the first over-the-counter test for flu. The test involves nasal swabbing and runs on two AA batteries, delivering a result in about 30 minutes. The introductory price is $34.99, and the product is available on the company's website.

Erik Engelson, MBS, MS, the company's president and chief executive officer, said, "US consumers will, for the first time ever, be able to diagnose if they have COVID-19 or Flu A or B while at home. With one-touch access to telehealth via our Lucira Connect web platform, they can now get onto the path to treatment and recovery within hours of receiving a test result from the comfort of home.”

Last month as the company received the EUA from the FDA it announced that it filed for bankruptcy due to the prolonged review process. The company said it had produced inventory for an autumn 2022 launch.

High path avian flu outbreaks strike more poultry in 7 states

News brief

12 minutes ago.
Lisa Schnirring
Topics

Avian Influenza (Bird Flu)

The US Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS), over the past few days, has reported more avian flu outbreaks in poultry from seven states.

In New York, the virus struck an upland gamebird producer in Tompkins County, plus a live bird market in Queens County that had 140 birds. South Dakota also reported an outbreak at an upland gamebird farm, a location in Spinks County that houses 570 birds. Michigan also reported an event involving a poultry farm, a producer in Lapeer County.

Also, four states reported more outbreaks in backyard poultry flocks. They include Colorado (Arapahoe County), Kansas (Ellsworth County), Oregon (Klamath County), and Texas (Hale County).

H5N1 outbreak activity in the US that began in February 2022 has now led to the loss of a record 58.6 million birds across 47 states, according to the USDA.
 
Back
Top Bottom